Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFMW) Non-Current Deferred Tax Liability (2022 - 2024)

Historic Non-Current Deferred Tax Liability for Sunshine Biopharma (SBFMW) over the last 3 years, with Q4 2024 value amounting to $389513.0.

  • Sunshine Biopharma's Non-Current Deferred Tax Liability rose 7273.84% to $389513.0 in Q4 2024 from the same period last year, while for Dec 2024 it was $389513.0, marking a year-over-year increase of 7273.84%. This contributed to the annual value of $389513.0 for FY2024, which is 7273.84% up from last year.
  • As of Q4 2024, Sunshine Biopharma's Non-Current Deferred Tax Liability stood at $389513.0, which was up 7273.84% from $48729.0 recorded in Q3 2024.
  • In the past 5 years, Sunshine Biopharma's Non-Current Deferred Tax Liability ranged from a high of $389513.0 in Q4 2024 and a low of $43032.0 during Q4 2022
  • For the 3-year period, Sunshine Biopharma's Non-Current Deferred Tax Liability averaged around $103702.3, with its median value being $48729.0 (2024).
  • Its Non-Current Deferred Tax Liability has fluctuated over the past 5 years, first skyrocketed by 42401.24% in 2023, then surged by 1323.9% in 2024.
  • Over the past 3 years, Sunshine Biopharma's Non-Current Deferred Tax Liability (Quarter) stood at $43032.0 in 2022, then skyrocketed by 424.01% to $225493.0 in 2023, then soared by 72.74% to $389513.0 in 2024.
  • Its Non-Current Deferred Tax Liability stands at $389513.0 for Q4 2024, versus $48729.0 for Q3 2024 and $48729.0 for Q2 2024.